US6869974B1
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compounds
Assignee: Nicox SA
•
Filing: 2000-04-11
•
Granted: 2005-03-22
•
Expires: 2020-04-11
Abstract
Abstract Compounds or their salts having general formulas (I) and (II): wherein s is an integer equal to 1 or 2, A is the radical of a drug that satisfies certain pharmacological tests, C and C 1 are bivalent radicals, and precursors of the radicals B and B 1 satisfy certain pharmacological tests.
Inventors
- 👤 Piero del Soldato
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 12:23
CPC Classifications
C; C07; C07D; C07D401/00; C07D401/02; C07D401/12; C07D235/00; C07D235/02; C07D235/04; C07D235/24; C07D235/28; A; A61; A61P; A61P39/00; A61P39/06; A61P43/00; C07C; C07C203/00; C07C203/02; C07C203/04; C07C219/00; C07C219/02; C07C219/18; C07C229/00; C07C229/52; C07C229/54; C07C229/64; C07C237/00; C07C237/48; C07C327/00; C07C327/20; C07C327/32; C07C327/34; C07D209/00; C07D209/02; C07D209/04; C07D209/10; C07D209/18; C07D219/00; C07D219/04; C07D219/08; C07D219/10; C07D233/00; C07D233/54; C07D233/64; C07D295/00; C07D295/04; C07D295/08; C07D295/084; C07D295/088; C07D401/14; C07D407/00; C07D407/02; C07D407/04; C07D417/00; C07D417/02; C07D417/12; C07D473/00; C07D473/02; C07D473/04; C07D473/06; C07D473/08; C07D473/18; C07D495/00; C07D495/02; C07D495/04; C07D499/00; C07D499/21; C07D499/44; C07D499/48; C07D499/58; C07D499/64; C07F; C07F9/00; C07F9/02; C07F9/28; C07F9/38; C07F9/3804; C07F9/3839; C07F9/3873; C07C2601/00; C07C2601/12; C07C2601/14; C07C2603/00; C07C2603/02; C07C2603/40; C07C2603/42; C07C2603/44; C07C2603/46
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
329 words
A compound or its salt having the following general formula (I): A—B—C—N(O) 2 (I) wherein: A=R—T 1 —, wherein R is the radical of the drug, as defined hereunder, having the formula R—T 1 —Z or R—T 1 —OZ in which Z is H or C 1 -C 5 alkyl, selected from the following classes: anti-inflammatory drugs: acetylsalicylic acid, 5-aminoacetylsalicylic acid, carprofen, diclofenac sodium salt, diflunisal, etodolac, flufenamic acid, flunixin, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, naproxen, niflumic acid, olsalazine, piroxicam, salsalate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, tolmetin and zomepirac; bronchodilators drugs: albuterol, carbuterol, clenbuterol, diphylline, etofylline, fenoterol, metaproterenol, pirbuterol, salmeterol and terbutaline; expectorant drugs: ambroxol, bromexine and guaiacol; antitumoral drugs: anthramycin, daunorubicin, doxorubicin and epirubicin; antibiotics drugs: amoxicillin, ampicillin, aztreonam, biapenem, carbenecillin, cefaclor, cefadroxil, cefamandole, cefatrizine, cefoxitin, dicloxacillin, imipenem, meclocycline, methacycline, moxalactam, panipenem, bacampicillin, apicycline, clomocycline and oxytetracycline; bone resorption inhibitors: alendronic acid, etidronic acid and pamidronic acid; antidementia drugs: tacrine; T 1 =(CO), O, S, or NR 1C , wherein R 1C is H, C 1 -C 5 alkyl, or a free valence; B=—T B —X 2 —T BI wherein T B and T BI are equal or different, T B is (CO) when T 1 is (CO), O, S, or NR 1C , wherein R 1C is as above defined, T B is O when T 1 is (CO), TBI is (CO) or O; X 2 is a bivalent bridging group such as the corresponding precursor of B, having the formula Z′—T B —X 2 T BI —Z″ in which Z′, Z″ are independently H or OH, is selected from the following compounds: Hydroxyacids: ferulic acid (DII), caffeic acid (DV), hydro caffeic acid (DVI), p-coumaric acid (DVII): C is the bivalent —T C —Y— radical, wherein T C is (CO) when T BI is O, T C is O when T BI is (CO); Y is a linear or branched (C 1 -C 20 )-alkylenoxy group
Claim 2
Dependent Claim
329 words
A compound or its salt having the following general formula (I): A—B—C—N(O) 2 (I) wherein: A=R—T 1 —, wherein R is the radical of the drug, as defined hereunder, having the formula R—T 1 —Z or R—T 1 —OZ in which Z is H or C 1 -C 5 alkyl, selected from the following classes: anti-inflammatory drugs: acetylsalicylic acid, 5-aminoacetylsalicylic acid, carprofen, diclofenac sodium salt, diflunisal, etodolac, flufenamic acid, flunixin, flurbiprofen, ibuprofen, indomethacin, indoprofen, ketoprofen, ketorolac, lornoxicam, loxoprofen, meclofenamic acid, mefenamic acid, meloxicam, mesalamine, naproxen, niflumic acid, olsalazine, piroxicam, salsalate, sulindac, suprofen, tenoxicam, tiaprofenic acid, tolfenamic acid, tolmetin and zomepirac; bronchodilators drugs: albuterol, carbuterol, clenbuterol, diphylline, etofylline, fenoterol, metaproterenol, pirbuterol, salmeterol and terbutaline; expectorant drugs: ambroxol, bromexine and guaiacol; antitumoral drugs: anthramycin, daunorubicin, doxorubicin and epirubicin; antibiotics drugs: amoxicillin, ampicillin, aztreonam, biapenem, carbenecillin, cefaclor, cefadroxil, cefamandole, cefatrizine, cefoxitin, dicloxacillin, imipenem, meclocycline, methacycline, moxalactam, panipenem, bacampicillin, apicycline, clomocycline and oxytetracycline; bone resorption inhibitors: alendronic acid, etidronic acid and pamidronic acid; antidementia drugs: tacrine; T 1 =(CO), O, S, or NR 1C , wherein R 1C is H, C 1 -C 5 alkyl, or a free valence; B=—T B —X 2 —T BI wherein T B and T BI are equal or different, T B is (CO) when T 1 is (CO), O, S, or NR 1C , wherein R 1C is as above defined, T B is O when T 1 is (CO), TBI is (CO) or O; X 2 is a bivalent bridging group such as the corresponding precursor of B, having the formula Z′—T B —X 2 T BI —Z″ in which Z′, Z″ are independently H or OH, is selected from the following compounds: Hydroxyacids: ferulic acid (DII), caffeic acid (DV), hydro caffeic acid (DVI), p-coumaric acid (DVII): C is the bivalent —T C —Y— radical, wherein T C is (CO) when T BI is O, T C is O when T BI is (CO); Y is a linear or branched (C 1 -C 20 )-alkylenoxy group
Claim 3
Dependent Claim
22 words
The compound or salt according to claim 1 , wherein Y is a linear or branched (C 1 -C 6 )-alkylenoxy group.
Claim 4
Dependent Claim
20 words
The compound or salt according to claim 1 , wherein the bivalent bridging group X 2 is ferulic acid (DII).
Claim 5
Dependent Claim
22 words
The compound or salt according to claim 3 , wherein Y is a linear or branched (C 1 -C 6 )-alkylenoxy group.
Claim 6
Dependent Claim
19 words
A drug comprising the compound or salt according to claim 1 , in combination with a pharmaceutically acceptable carrier.
Claim 7
Dependent Claim
16 words
A pharmaceutical formulation containing the compound or salt according to claim 1 as an active component.
Claim 8
Dependent Claim
31 words
A method for treating oxidative stress dysfunction, said method comprising administering a therapeutically effective amount of the compound or salt according to claim 1 , to a patient in need thereof.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2008-03-21 | 2008-09-20 | 2009-03-22 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2012-03-21 | 2012-09-20 | 2013-03-22 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2016-03-21 | 2016-09-20 | 2017-03-22 | $7700.00 | Window Closed / Lapsed |